PriceTracker GLP-1
Loading the index…

Try

Loading the index…

Try

GLP-1 TV · Patient story · views checked Oct 2026

Wow!😲MOUNJARO 3 Month Results😲|5mg | WEIGHT LOSS, Blood Sugar Levels, etc | 90 Days on Tirzepatide

Patient storyThe.Patrice.Denise45,275 views13:24Feb 2023

Our summary

Patrice, who says she has been diagnosed with type 2 diabetes in the past, gives a 90 day update on taking Mounjaro. She says she switched from Ozempic because of a shortage at the end of 2022 and started Mounjaro on November 30, 2022. Her starting weight was 191.4 pounds on December 1, 2022. She reports losing 9.4 pounds in month one on 2.5 mg, 3 pounds in month two on 5 mg, and 2.6 pounds in month three, also on 5 mg, for a total of 15 pounds. She says she gained 1.6 pounds in week 12 and now weighs 176.4 pounds.

One person's experience, in their words. Not medical advice.

What else the video covers

She spends much of the video on blood sugar. Patrice says she checks her fasting blood sugar each morning and gives weekly averages. She reports a drop from 112 in week two to 94 in week 11 and 97 in the most recent week. She says her last A1C was 5.9, that she does not recheck it with her provider until May, and that she expects it to be lower. She also reports that her abdomen measurement fell from 38.5 inches to 35.77 inches, against her goal of getting under 35 inches.

On side effects, she describes decreased appetite that fades around day six or seven after the injection, constipation that she manages with Miralax, a store-brand Metamucil and a stool softener, a lasting full feeling after heavy meals, and fatigue the day after her injection. She says she has had no nausea, vomiting or diarrhea in the past month. She plans to ask her provider about staying on 5 mg rather than moving to 7.5 mg, and says she is starting month four on 5 mg.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 1:01 Patrice says she went from 191.4 pounds to 176.4 pounds over 90 days, a total loss of 15 pounds, after 9.4 pounds in month one, 3 pounds in month two and 2.6 pounds in month three.
  2. 3:10 She reports her average fasting blood sugar trended down from 112 in week two to 94 in week 11 and 97 in the latest week, and she expects her A1C, last 5.9, to be lower.
  3. 6:15 She says her abdomen measurement went from 38.5 inches to 35.77 inches, with a goal of getting below 35 inches.
  4. 8:18 She lists decreased appetite, manageable constipation, a lasting full feeling and fatigue the day after injecting as her side effects, with no nausea, vomiting or diarrhea in the past month.
  5. 11:20 She says she is leaning toward staying on 5 mg rather than going to 7.5 mg, and will start month four on 5 mg after checking with her provider.

Key moments

From the creator's own chapters. Tap one to play from there.

  1. 0:00 Intro
  2. 1:02 Weight Loss
  3. 2:26 Overall Results
  4. 3:23 Blood Sugar Levels
  5. 4:06 Blood Sugar Trends

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Mounjaro and tirzepatide
Doses mentioned
2.5 mg, 5 mg and 7.5 mg
Point in the journey
Month 3
Side effects mentioned
constipation and fatigue
Who is speaking
Patient

Questions this video answers

How much weight did she lose on Mounjaro in 3 months?

Patrice says she lost a total of 15 pounds in 90 days, going from 191.4 pounds to 176.4 pounds. She reports 9.4 pounds in month one on 2.5 mg, 3 pounds in month two on 5 mg and 2.6 pounds in month three on 5 mg.

How did Mounjaro affect fasting blood sugar for someone with type 2 diabetes?

Patrice says her average fasting blood sugar was 112 in week two and fell to 94 in week 11, then 97 in the most recent week. She says her last A1C was 5.9 and that she expects the next one to be lower.

What side effects did she have on Mounjaro 5 mg?

Patrice reports decreased appetite that wears off around day six or seven after injecting, constipation she manages with Miralax, Metamucil and a stool softener, and a long lasting full feeling after heavy meals. She also reports fatigue the day after her injection and no nausea, vomiting or diarrhea in the last month.

Did Mounjaro reduce her waist size?

Patrice says her abdomen measurement dropped from 38.5 inches to 35.77 inches over three months. She says her goal is to get below 35 inches.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Mounjaro side effects: the label's numbers by dose, the low blood sugar risk, and how tirzepatide compares at weight-loss doses

    On Mounjaro's own label, the common side effects are stomach ones and they rise with the dose: nausea in 12, 15 and 18 percent of people at 5, 10 and 15 mg against 4 percent on placebo, diarrhea 12 to 17 against 9, and any gastrointestinal reaction in 37 to 44 percent against 20. Most of it happens while the dose is being raised and fades. Low blood sugar is rare on Mounjaro alone and is mainly a risk when it is added to insulin or a sulfonylurea. Below: the full table, the rare warnings, and why Zepbound's numbers for the same molecule look higher.

  • Mounjaro for weight loss, and why Zepbound exists

    Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is the same molecule from the same maker, approved for weight management, and it goes to the same 15 mg. So unlike Ozempic and Wegovy, there is no dose ceiling pushing you from one to the other: the reason people move is coverage and cash price, not strength. Using Mounjaro for weight is off-label and a prescriber's decision. In the one head-to-head trial, tirzepatide beat semaglutide, 20.2% mean body-weight loss at 72 weeks against 13.7%.

  • Mounjaro vs Ozempic, and the trial everyone quotes about it

    Mounjaro is tirzepatide and Ozempic is semaglutide: different molecules, not two brands of the same drug. Both are approved for type 2 diabetes, and the weight-loss versions are Zepbound and Wegovy. In the one head-to-head trial, SURMOUNT-5, tirzepatide produced 20.2% mean body-weight loss at 72 weeks against semaglutide's 13.7%. The detail almost every page omits: that trial dosed semaglutide to 2.4 mg in people without diabetes, which is the Wegovy range. Ozempic tops out at 2 mg. The famous result did not test Ozempic's dose range.

Find more like it

Side effectsDose changeWeigh-in and resultsFood, protein and eatingFood noise and cravingsExercise and strengthHow it worksConstipationFatigue

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV